DBV (DBVT) Revenue & Revenue Breakdown
DBV Revenue Highlights
0
Latest Revenue (Q)
$1.16M
DBV Revenue by Period
DBV Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $4.80M | -15.91% |
| 2021-12-31 | $5.71M | -49.38% |
| 2020-12-31 | $11.28M | -23.33% |
| 2019-12-31 | $14.71M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2016-12-31 | $202.00K | -8.53% |
| 2015-12-31 | $220.85K | -13.83% |
| 2014-12-31 | $256.29K | 2.09% |
| 2013-12-31 | $251.04K | 8.87% |
| 2012-12-31 | $230.59K | 41.14% |
| 2011-12-31 | $163.37K | - |
DBV generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
DBV Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $1.16M | -17.48% |
| 2024-03-31 | $1.41M | -84.15% |
| 2023-12-31 | $8.88M | 269.79% |
| 2023-09-30 | $2.40M | 4.90% |
| 2023-06-30 | $2.29M | 4.28% |
| 2023-03-31 | $2.19M | -268.25% |
| 2022-12-31 | $-1.30M | -162.87% |
| 2022-09-30 | $2.07M | 35.64% |
| 2022-06-30 | $1.53M | -39.95% |
| 2022-03-31 | $2.55M | -55.40% |
| 2021-12-31 | $5.71M | 331.44% |
| 2021-09-30 | $1.32M | -188.91% |
| 2021-06-30 | $-1.49M | -150.60% |
| 2021-03-31 | $2.94M | -73.92% |
| 2020-12-31 | $11.28M | 171.19% |
| 2020-09-30 | $4.16M | 15.18% |
| 2020-06-30 | $3.61M | -23.52% |
| 2020-03-31 | $4.72M | 182.22% |
| 2019-12-31 | $1.67M | -33.46% |
| 2019-09-30 | $2.51M | -25.98% |
| 2019-06-30 | $3.40M | 1.38% |
| 2019-03-31 | $3.35M | -6.75% |
| 2018-12-31 | $3.59M | 40.28% |
| 2018-09-30 | $2.56M | -24.94% |
| 2018-06-30 | $3.41M | -5.21% |
| 2018-03-31 | $3.60M | 87.39% |
| 2017-12-31 | $1.92M | 1.51% |
| 2017-09-30 | $1.89M | -48.22% |
| 2017-06-30 | $3.65M | 7.06% |
| 2017-03-31 | $3.41M | - |
DBV generated $1.16M in revenue during Q2 2024, up -17.48% compared to the previous quarter, and up 52.92% compared to the same period a year ago.
DBV Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IPHA | Innate Pharma | $51.90M | $16.56M |
| GNFT | Genfit | $28.57M | $17.08M |
| TARS | Tarsus Pharmaceuticals | $17.45M | $48.12M |
| ITOS | iTeos Therapeutics | $12.60M | $35.00M |
| IKNA | Ikena Oncology | $9.16M | - |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| CNTA | Centessa Pharmaceuticals | $6.88M | - |
| HCWB | HCW Biologics | $2.84M | $426.42K |
| INBX | Inhibrx Biosciences | $1.80M | - |
| LYRA | Lyra Therapeutics | $1.56M | $195.00K |
| MNOV | MediciNova | $1.00M | - |
| OPT | Opthea | $108.41K | $61.27K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| NUVL | Nuvalent | - | - |
| EPIX | ESSA Pharma | - | - |
| CELC | Celcuity | - | - |
| ORIC | ORIC Pharmaceuticals | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| DBVT | DBV | - | $1.16M |